Thursday, 2 July 2020

Vocal Cord Paralysis Market 2020 Size, Business Research, Revenue, Growth Insights To 2023

Global Vocal Cord Paralysis Market: Information by Type (Unilateral and Bilateral), Treatment (Voice Therapy and Surgery) and Region (Americas, Europe, Asia-Pacific and the Middle East & Africa) - Forecast till 2023
Market Dynamics
Vocal Cord Paralysis Market is driven by rising prevalence of causing factors of vocal cord paralysis and technological advancements. For instance, according to the American Cancer Society, the estimated number of new cancer cases involving larynx was 13,360 in the US for the year 2017. Moreover, increasing healthcare expenditure has fueled the growth of the market. On the other hand, the high cost of treatment is anticipated to hamper the market growth.
Market Scenario
The Global Vocal Cord Paralysis Market Growth is expected to register a CAGR of 3.8%and is anticipated to reach USD 2,920.2 Million by 2023. Vocal cord paralysis is caused by the disruption of nerve impulses to the muscles of the larynx or voice box. It may be caused by injury to the head, neck, or chest; lung or thyroid cancer; tumors of the neck or chest; or infection. The nerves controlling the vocal cords are long and can be vulnerable to injury in parts of the body, not usually associated with the vocal cords.
The increasing prevalence of causing factors of vocal cord paralysis, technological advancements, and growing healthcare expenditure are the major drivers propelling market growth. However, the high cost associated with the treatment is expected to constrain the growth of the market.
Competitive Landscape
Key players in the vocal cord paralysis market include Cytophil, Inc. (U.S.), Teleflex Incorporated (U.S.), Medtronic Plc (U.S.), Olympus Corporation (Japan), Stryker Corporation (U.S.), FUJIFILM Holdings Corporation (Japan), LifeCell Corporation (U.S.), Therapy Solutions Inc. (U.S.), KARL STORZ GmbH & Co. KG (Germany), and Smiths Group Plc (U.K.).
The report offers a comprehensive analysis on the profiles on these market players and assesses their current standing in the market. Company history coupled with annual turnover, profit margins, segmental share, SWOT analysis, growth strategies, expansion techniques, and latest R&D initiatives are discussed in minute detail.
Segmentation
By type, the market is divided into unilateral and bilateral. Treatment options in the vocal cord paralysis market voice therapy and surgery. The surgery treatment segment is further divided into structural implants, tracheotomy, bulk injection (phonosurgery), and vocal cord repositioning. The segments covered in the vocal cord paralysis market report are analyzed with respect to four regions namely – Americas, Middle East & Africa (MEA), Asia Pacific (APAC), and Europe. The report discusses in detail the various players residing in these regions and their respective strategies to climb up the market standings.
Regional Analysis
By region, the global vocal cord paralysis market has been segmented into the Americas, Asia Pacific (APAC), Europe, and the Middle East & Africa (MEA).
The Americas accounted for the largest share of 35.4% share of the global market in 2017 and is due to reach USD 1,007.5 Mn in 2023 at a CAGR of 3.4% by the end of the forecast period. Robust healthcare sector, technological superiority, and rising expenditure ion healthcare sector drive the market in the Americas. In addition, the region is highly aware of the medical condition which is acts a plus for the growth of the market.
Europe is a prominent market for vocal cord paralysis and is likely to scale valuation of USD 958.1 Mn at a CAGR of 4% by the end of the forecast period. Similar factors spur the Europe market as the Americas. Also, favorable reimbursement policies and high government support create a conducive environment for the growth of the Europe vocal cord paralysis market.
APAC vocal cord paralysis market is likely to exhibit rapid growth over the forecast period and emerge as the fastest growing market over the forecast period. The increasing prevalence of laryngeal cancer, availability of affordable treatment options and high expenditure on healthcare drive the market in APAC. The APAC market is expected to capture a CAGR of 4.11% over the forecast period.
The MEA market for vocal cord is expected to hold the least share of the market and expand at a CAGR of 3.90% over the forecast period.
Browse Vocal Cord Paralysis Market Report Information by Type, Treatment and Region @ https://www.marketresearchfuture.com/reports/vocal-cord-paralysis-market-5079
Posted by at No comments:

Global Herbal Medicine Market Drivers, Segmentations, Key Players, Analysis & Forecast 2020 - 2023

Herbal Medicine Market Analysis
Herbal medicines are developed using various parts of plants such as bark, flowers, leaves, seeds, bark, etc. Modern methods have made it possible for these medicines to adopt forms of capsules, tablets, powders, and syrups. The global herbal medicine market report by Market Research Future (MRFR) outlines pertinent drivers, challenges, trends, and opportunities for the period of 2018 to 2023 (forecast period).
Get a FREE Sample with Complete TOC By Considering the COVID-19 impact on Global Market @ https://www.marketresearchfuture.com/sample_request/3250
Herbal Medicine Market Outlook
The global herbal medicine market is predicted to reach a valuation of USD 129,689.3 million by 2023. It is expected to expand at 5.88% CAGR over the forecast period. Massive demand for herbal medicines, multiple applications of herbal medicines, and increased funding for research into the effects of these medicines are major drivers of the market. According to the National Center for Biotechnology Information, around 70-80% of the population relied on natural medicines for their treatment. Awareness of alternative medicines owing to the advent of social media is likely to augur well for the market.
However, side-effects to herbal and low number of standards can negatively impact the market growth.
Herbal Medicine Market Competition Outlook
Venus Pharma GmbH, Hishimo Pharmaceuticals, Schaper & Brümmer, Himalaya Global Holdings Ltd, Dr. Willmar Schwabe India Pvt. Ltd., Arizona Natural Products, Bayer AG, Blackmores, BEOVITA, Arkopharma, ZeinPharma Germany GmbH, and Dasherb Corp. are prominent names in the global herbal medicine market. Entry of newcomers to the industry as well as attempts to carve their niches to control market share can be witnessed in the coming years.
Herbal Medicine Market Segmentation
The global herbal medicine market is segmented by category, type of medicinal plants, form, source, and distribution channel.
The global herbal medicine market, by category, has been segmented into herbal beauty products, herbal pharmaceuticals, herbal dietary supplements, and herbal functional foods. Herbal pharmaceuticals accounted for 54.9% market share in 2017.
Based on type of medicinal plants, the herbal medicine market has been categorized as cinnamomum spp, echinacea, marrubium vulgare, cocos nucifera, vaccinium macrocarpon, curcuma longa, aloe vera, camellia sinensis, actaea racemose, zingiber officinale, and allium sativum.  Marrubium vulgare is expected to be the leading segment of the market till 2023.
Based on form, the herbal medicine market has been classified as syrups, extracts, powders, and capsules & tablets.
Based on the source, the herbal medicine market has been divided into whole plants, leaves, root & barks, and fruits.
By distribution channel, the global herbal medicine market has been bifurcated into hospital & retail pharmacies and E-commerce. The hospital & retail pharmacies segment is expected to account for a large market share owing to the demand for drugs and medicines amid prevalence of chronic diseases.
Herbal Medicine Market Regional Analysis
The global herbal medicine market, based on region, is divided into the Americas, Europe, Asia Pacific (APAC), and the Middle East & Africa (MEA).
Europe is predicted to lead the market owing to preference for herbal drugs, rise in funding for research on herbal plants, and rising inclination towards natural products. Development of herbal medicines which are quick to act and provide immediate symptomatic relief can lead to good returns for the global market till the end of the forecast period.
APAC is anticipated to be the second-largest region owing to adoption of traditional medicinal formulations by researchers, pharmaceutical companies, and policy makers. The geriatric populace and use of healthcare IT for making patients aware of alternative medicines can drive the regional market growth. Initiatives by the healthcare departments of economies to commence clinical trials on the effects of herbal medicines on COVID-19 can augur favorably for the market.
The Americas is predicted to follow APAC in rankings owing to the use of herbal medicines by the denizens of countries in the region. According to the National Center for Biotechnology Information, herbal supplements were used for cancer, arthritis, and strokes in the U.S.
Lastly, the MEA region is seen to be registering a slow growth rate owing to less awareness of herbal drugs. 
Obtain Premium Research Report Details, Considering the impact of COVID-19 @ https://www.marketresearchfuture.com/reports/herbal-medicine-market-3250
Posted by at No comments:

Global Telehealth Market 2020 Business Insights & Deep Analysis To 2024 By World’s Top 10 Key Players

Telehealth Market Insight
The global Telehealth market is rising continually, improving supportive care for various chronic diseases. Besides, significant benefits offered by telehealth, such as improved outcomes and enhanced care-coordination, drive the market growth, improving clinical efficiency & consumer engagement. Moreover, the recent COVID-19 outbreak has given a healthy boost to the telehealth market.
Technology is the core of telehealth, as it enables patients to connect with medical professionals from their homes' safety and comfort. When some HIPPA regulations waived due to the coronavirus pandemic, telehealth assisted patients using a HIPPA-compliant platform, such as SimplePractice or Zoom for Healthcare. Furthermore, the paradigm shift toward more organized and continuous healthcare monitoring accelerate the growth of the market.
Get a FREE Sample with Complete TOC By Considering the COVID-19 impact on Global Market @ https://www.marketresearchfuture.com/sample_request/900
According to Market Research Future (MRFR), the global Telehealth market is expected to create a valuation of USD 16,173.8 Million by 2024, growing at a robust CAGR of 22.74% throughout the forecast period (2019–2024). Rising prevalence of myriads of chronic disorders, increasing cases of severe road accidents, and trauma cases, has helped market growth. Besides, the proliferation of the internet, smartphones, connected devices, and advances in telemedicine technologies act as key driving forces.
Additionally, factors such as the increasing geriatric population, technological advances in the healthcare sector, and growing cases of patients affected by chronic diseases worldwide are expected to drive the growth of the market. Rising R&D spending and aggressive growth strategies adopted by top players, such as new product launches, contribute to the increase of the market.
On the other hand, the lack of adequate reimbursement policy and high costs involved in the deployments of telehealth devices are the factors estimated to impede the growth of the market. Nevertheless, the rising uptake of telehealth would support market growth throughout the assessment period.  
Impact 0f COVID-19 on the Telehealth Market
WHAT HAS CHANGED WITH COVID-19?
Statistically, 40% of doctors are providing care to coronavirus patients, and rest 60% of doctors are forced to stop their services until told otherwise. Social distancing and lockdowns across the countries due to COVID-19 have forced non-urgent healthcare providers to close their doors and pushed many patients to seek care remotely. Due to the uncertainty of the COVID-19 crisis, a number of care providers are thinking about changing their service model and implementing the telehealth solutions as part of their regular medical setup. Telehealth is no longer a supplementary care option but a must-have option for healthcare professionals and patients.
Given the debilitating impact of COVID-19 (Coronavirus) on Telehealth Market, companies are on the lookout for starting production lines. Get an inside look at the market prospects and its future decisions in light of the pandemic and other such unforeseen circumstances.
Global Telehealth Market -   Segmentations
The report is segmented into four dynamics;
By Component: Services (Remote Monitoring, Real-Time Interactions, Store-and-Forward Consultations, others), Hardware {Monitoring Devices (Stationary and Wearable), Medical Peripherals (Blood Pressure Monitors, ECG Monitors, Pulse Oximeters, Blood Glucose Meters, Peak Flow Meters, Otoscopes, others)}, others, Software (Integrated Software, Standalone Software, others), and others.
By Mode of Delivery: Web/Cloud-Based, On-Premise, and others.
By Application: Radiology, Cardiology, Primary Care, Neurophysiology, and others.
By Regions: Americas, Europe, Asia Pacific, and the Rest-of-the-World. 
Global Telehealth Market - Regional Analysis
North America dominates the global Telehealth market. The largest telehealth market share attributes to the increasing adoption of telehealth services across the region. Besides, considerable advancements in healthcare-related technologies and surging cases of hospitalizations in the region drive the growth of the market. Also, the rising prevalence of chronic diseases & disorders, road accidents, and traumatic incidents and growing geriatric populaces foster regional market growth.
Moreover, the proliferating home-based care services, key industry players, and increasing numbers of hospitals and clinics in the region, influences the market growth. Additionally, the well-developed healthcare infrastructure and the high healthcare expenditure in the region, act as a significant tailwind for the market growth. Furthermore, the increasing adoption of tele- ICU led by favorable government policies and increased incentives drive the regional market growth.
Europe accounts for the second-largest share in the global Telehealth market. The growth is driven by the increasing demand for connected healthcare systems that can provide real-time data and encouraging government funding support for R&D and in the healthcare sector. Moreover, favorable reimbursement policies are contributing to the growth of the market in this region.
Rising focus on more organized and continuous healthcare monitoring in the region is a significant tailwind for the growth of the market. Germany is the largest Telehealth market in the region, leading the connected healthcare deployments in Europe. Besides, increased digitization and focus on data quality management, data integration, and data governance, boost the growth of Telehealth market in the European region.
The telehealth market is rapidly emerging in the Asia Pacific region. The telehealth concept is catching a rapid momentum in the region. Besides, the region observes the increasing adoption of telehealth in quadrupling numbers of healthcare facilities. The APAC market demonstrates tremendous development opportunities due to the continually developing healthcare infrastructure in the region, which, in turn, acts as significant tailwinds pushing up the growth in the market.  Rapidly developing countries, India, China, and Japan, contribute to the regional market growth majorly, witnessing the wide adoption of tele-ICU management products. 
Global Telehealth Market – Competitive Landscape
Highly competitive, the telehealth market appears to be fragmented due to the presence of many well-established players. Players initiate strategies such as mergers & acquisitions, collaboration, and innovations and invest colossal amounts. Investments are majorly used to bring innovations as well as to expand their market presence. They also make substantial investments in R&D activities to develop a cost-effective product portfolio. These players focus on optimizing situational awareness towards customers to ensure their mission success. 
Telehealth Market Major Players 
Players leading the global telehealth market include AMD Global Telemedicine Inc. (US), Boston Scientific Corporation (US), Siemens (Germany), Right Health (Canada), Allscripts Healthcare Solutions (US), American Well (US), Care Innovations LLC (US), GlobalMed (US), Honeywell International Inc. (US), Medtronic PLC (Ireland), InTouch Technologies Inc. (US), Philips Healthcare (Netherlands), Dialogue (Canada), Cerner Corporation (US), Maple (Canada), Livecare Health (Canada), and Cisco Systems Inc. (US), among others. 
Telehealth Industry/Innovation/Related News:
June 07, 2020 ---- American Medical Group Association (AMGA), asked the Centers for Medicare & Medicaid Services (CMS) to permanently extend the telehealth flexibilities it instituted as a result of the COVID-19. The reality of the coronavirus crises has necessitated widespread use of telemedicine in the US, imposing social distancing, stay-at-home orders, and quarantines. Now that these capabilities have been established well and hence, telehealth flexibilities should not be rolled back, After COVID-19 Pandemic, states AMGA. 
Obtain Premium Research Report Details, Considering the impact of COVID-19 @ https://www.marketresearchfuture.com/reports/telehealth-market-900
Posted by at No comments:

Chemotherapy Market 2020 Size, Business Research, Revenue, Growth Insights To 2024

Market Scenario:
Chemotherapy Market 2019 offered by Market Research Future (MRFR), The Global Chemotherapy Market is Expected to register a CAGR of 11.50% to reach USD 56,491.59 Million by 2024. Global Chemotherapy Industry by Drug Class, Indication, Route of Drug Administration and End-User and Forecast till 2024
The increasing prevalence of cancer, increasing expenditure on oncology medicine and research, and reimbursements and growing health insurance are driving the growth of the global chemotherapy market. 
Market Dynamics
The global Chemotherapy Market Growth has been largely benefited by the increasing demand for chemotherapy devices market across the world. Increasing prevalence of cancer; increasing expenditure on oncology medicine and research, and reimbursements and growing health insurance are expected to spur market growth during the forecast period. Moreover, the patent expiry of leading drugs, government initiatives, and increasing public awareness about various diseases and treatment options are further expected to boost the growth of the global chemotherapy market during the review period.
Chemotherapy is one of the types of cancer treatment, which includes the use of one or more chemotherapeutic agents such as anti-cancer drugs. The treatment prevents the division of cancer cells and the growth of cancer cells by killing dividing cells. It is used for the treatment of various types of cancers such as lung cancer, breast cancer, leukemia, myeloma, sarcoma, lymphoma, ovarian cancer, and others.
Segmentation
The Global Chemotherapy has been segmented into major four segments, including drug class, route of administration, indication, and end user.
On the basis of drug class, the market is segmented into alkylating agents, mitotic inhibitors, antimetabolites, topoisomerase inhibitors, and antitumor antibiotic. The alkylating agents segment is expected to lead the market and register a substantial CAGR to reach USD 20,360.32 million by the end of 2024 and projected to exhibit the highest CAGR of 11.83% from 2019 to 2024.
Furthermore, based on indication, the market is segmented into lung cancer, breast cancer, colorectal cancer, prostate cancer, stomach cancer, lymphoma, leukemia, ovarian cancer, and others.  Lung cancer accounted for the largest market share and expected to grow with the CAGR of 11.88% during the forecast period.
On the basis of route of administration, the market is segmented into intravenous, oral, subcutaneous, intra-muscular, intravesicular, topical, intraperitoneal, and intraventricular/intrathecal. Intravenous accounted for the largest market share. However, the oral segment is expected to grow at the fastest CAGR of 11.95% during the forecast period.
On the basis of end user, the market is segmented into, specialty centers, hospitals & clinics, others
Key Players
The prominent players in the global chemotherapy market are Johnson & Johnson Services Inc (US), GlaxoSmithKline PLC (UK), Eli Lilly and Company (US), F. Hoffmann-La Roche Ltd (Switzerland), Novartis AG (Switzerland), Pfizer Inc. (US), Merck & Co. Inc. (US), Sanofi S.A. (France), Celgene Corporation (US) and Bristol-Myers Squibb Company (US).
Regional Analysis
Geographically the chemotherapy market is divided into the Americas, Europe, Asia-Pacific, and the Middle East and Africa.
Americas accounted for the largest market share of 41.04% in 2018, and the regional market is projected to register a CAGR of 10.88%during the forecast period. North America is one of the leading markets in the region, accounting for the largest market share during the review period.  
The European market is estimated to exceed USD 18,292.73 Million by 2024. The accessibility to advanced treatment facilities, rising government initiatives to promote research to find a cure to the increasing number of cancer cases, and growing healthcare expenditure are driving the growth of the chemotherapy market in the region. Germany is the major contributor to the growth of the regional market, followed by France.
The market in Asia-Pacific is expected to be the fastest growing market. This high growth is mainly attributed to the increasing R&D funding by developing countries such as China and India for the development of the healthcare sector. Various other factors that influence the growth of the market include growing incidence of cancer, aging population, increasing demand for advanced therapies, patent expiry of leading drugs, government initiatives, and increasing public awareness about various diseases and treatment options.
The Middle East & Africa commands the least market share of the chemotherapy market, owing to fewer developments and extremely low income but, is expected to grow with better chemotherapy treatments. As the population is rapidly aging, cancer treatment is expected to increase in this region
Posted by at No comments:

Worldwide Cardiopulmonary Disease Diagnostics and Treatment Market 2019 Synopsis With Leading Players, Industry Growth Factor Foresight By 2023

Market Scenario:
The cardiopulmonary disease is a general term used to describe a variety of different diseases and conditions related to heart and lungs. Cardio Vascular Disease is a complex disease with a wide variety of risk factors including those that are modifiable, such as physical inactivity, non-modifiable factors such as age, genes, congenital dispositions, and gender. Respiratory disease is a medical term that includes extreme conditions affecting the organs and tissues which make gas exchange possible in higher organisms. Depending upon the type of cardiopulmonary disease present the treatment options vary and may include changes in diet or lifestyle, use of medications issued on prescription or surgery. The most common cardiopulmonary diseases are hypertension, stroke, and coronary heart disease. Untreated, cardiopulmonary diseases can be deadly. Cardiopulmonary diseases are the major cause of death globally.
The substantial growth in the frequency of health conditions related to the lungs and heart is the key factor to boosts the growth of this market. Also, the increase in aged population and the rising frequency in cardiovascular and respiratory diseases is also anticipated to drive the global market over the forecast period. Exposure to nicotine, tobacco products, and others increases the risk of obtaining cardiopulmonary diseases.
Increase in the rise of advanced technological equipment for diagnosing the disease will drive market rate exponentially. However, the huge cost of treatment and the regulatory nature of government on pharmaceutical companies will hamper the Cardiopulmonary Disease Diagnostics and Treatment market.
Key Players
  • Cardinal Health
  • Cosmed Medical
  • GE Healthcare
  • Halma plc
  • Hill-Rom Holdings, Inc.
  • Koninklijke Philips N.V.
  • MGC Diagnostics Corporation
  • NIHON KOHDEN CORPORATION
  • Schiller AG
  • Masimo Corporation
  • Vyaire Medical Inc
Segmentation
The global cardiopulmonary disease diagnostics and treatment market has been segmented on the basis of disease type, type, and end-user.
On the basis of disease type, the market has been classified as cardiovascular and respiratory diseases. The cardiovascular diseases are segmented into coronary artery disease, angina pectoris, myocardial infarction, dysrhythmia, hypertension, and others. The respiratory diseases are segmented into influenza, asthma, bronchitis, emphysema, cystic fibrosis, and others.
On the basis of end users, the market has been classified as hospitals, clinics, diagnostic centers, specialty clinics and rehab centers, research institutes and others.
On the basis of region, the market is segmented into the Americas, Europe, Asia-Pacific, and the Middle East and Africa. The Americas has been further segmented into North America and South America, with the North American market divided into the US and Canada.
On the basis of type, the market has been classified as diagnosis and treatment. The diagnosis market is segmented into an electrocardiogram (ECG), Holter monitoring, echocardiogram, stress test, cardiac catheterization, cardiac computerized tomography (CT) scan, cardiac magnetic resonance imaging (MRI), single-photon emission computed tomography (SPECT), stress blood pressure monitors, pulse oximeters and spirometry. The treatment market is segmented into medications. The medications segment is further sub-segmented into angiotensin-converting enzyme (ACE) inhibitors, angiotensin II receptor blockers (ARBS), anticoagulants, antiplatelet agents and others.
The European cardiopulmonary disease diagnostics and treatment market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. 
The cardiopulmonary disease diagnostics and treatment market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The cardiopulmonary disease diagnostics and treatment market in the Middle East and Africa has been segmented into the Middle East and Africa.
Posted by at No comments:

The Verrucous Carcinoma Market Grows Incredibly; Confirms Mrfr Unleashing Industry Prognostications Up To 2023

Market Insights
Verrucous Carcinoma typically debuts as an anomalous growth or as alteration in the constancy of an earlier potentially malignant ailment of the oral cavity. Verrucous Carcinoma is a rare, locally aggressive, clinically exophytic, low-grade, slow-growing, well-differentiated squamous cell carcinoma with nominal metastatic potential. It is unusual subtype of malignant ailment which affects oral cavity. Verrucous Carcinoma can affect all mucosal sites of the oral cavity. However, the frequency of malignant transformation of a leukoplakia to an OVC is considerably higher if they are in the gums in comparison to the tongue.
Verrucous Carcinoma is mainly caused by the snuffing of tobacco or chewing of tobacco. It is also referred to as snuff dipper's cancer. Verrucous Carcinoma mostly prevails at oral zones. The condition common in males within the age group 50 to 80 years. The increasing incidences of oral cancer primarily influences the market. Lifestyle factors such as smoking marijuana or tobacco and alcohol consumption mostly drives the Verrucous Carcinoma market. Additionally, growing consumption of alcohol, increasing adoption of sedentary lifestyle, increasing rates of sexually transmitted viruses by human papillomavirus, and family history of cancer prevalence contribute largely towards the development of the market. In 2015, the World Health Organization reported that 1.1 billion people smoked tobacco globally. This is likely to accelerate the market growth over the forecast period.
However, the high cost of surgical procedures, side effects associated with treatments, and expensive chemotherapy treatments are anticipated to limit the market growth to a certain extent.
Market Segmentation
The worldwide Verrucous Carcinoma market has been segmented based on treatment, end-user, and diagnosis.
Based on treatment, the Verrucous Carcinoma market has been segmented into radiation therapy, surgery, targeted drug therapy, and chemotherapy. Surgery has been sub-segmented into Mohs micrographic surgery and surgical excision. Chemotherapy has been sub-segmented into 5-fluorouracil, bleomycin, methotrexate, cisplatin, and others. Based on end-user, the Verrucous Carcinoma market has been segmented into ambulatory surgical centers, hospitals and clinics, research centers, diagnostic centers, and others. Based on diagnosis, the Verrucous Carcinoma market has been segmented into endoscopy, imaging tests, and biopsy. Imaging tests have been sub-segmented into magnetic resonance imaging, positron emission tomography scans, and computerized tomography scans.
Regional Analysis
The Americas represent the largest Verrucous Carcinoma market share in the global market. The market growth is owing to the increasing healthcare expenditure and surging prevalence of Human Papillomavirus (HPV). As recorded by the Genital HPV Infection, Fact Sheet 2017, 79 million American adults were infested with HPV. Europe (Belgium, UK, Netherlands, and France) represents the second largest Verrucous Carcinoma market over the forecast period. Rising prevalence of head and neck cancer drives the Verrucous Carcinoma market in this region. The Cancer Research UK revealed that in 2015, there were12061 new instances of neck and head cancer. These statistics substantially drive the Verrucous Carcinoma market in Europe.
In 2017, Asia-Pacific was estimated to be the fastest growing region for the worldwide Verrucous Carcinoma market. The market has been expected to develop owing to the rising addiction to smoking. According to the World Health Organization, in 2015, 33.7% and 47.6% of people smoked tobacco in Japan and China, respectively. The Middle East and Africa holds the least market share due to lack of availability of trained healthcare professionals and low per capita income in the region. Nevertheless, the growing palliative and oncology care services both at the community and the hospital level are expected to influence the market positively.
Key Players
The global Verrucous Carcinoma market is dominated by key players such as Qilu Pharmaceutical Co., Ltd. (Asia Pacific), Bristol-Myers Squibb Company (US), Eli Lilly and Company. (US), Teva Pharmaceutical Industries Ltd. (Israel), Merck & Co., Inc. (US), F. Hoffmann-La Roche Ltd (Europe), Pfizer Inc. (US), Novartis AG (Europe), and others.
Posted by at No comments:

Global Dyspepsia Market 2019 To 2023 Professional Overview, Detail Analysis, Growth And Top Key Players Demand

Market Scenario
Dyspepsia is a chronic medical condition which causes discomfort in the upper abdomen as a result of indigestion. The stomach and the small intestine, and sometimes the esophagus does not function properly which is the main reason for the discomfort. Gastritis, peptic ulcers, gallstones, stomach cancer, constipation, reduced blood flow in the intestine are other causes for dyspepsia. Overeating, over-consumption of alcohol and smoking, might also cause dyspepsia. The global dyspepsia market is perceived to be a steadily growing market as per the analysis of market Research Future (MRFR).
Surging prevalence of digestive diseases across the globe is one of the prime reasons for the growth of the global dyspepsia market size. The Centers for Disease Control and Prevention estimated 14.7 Mn people in the US to be suffering from digestive ulcers in 2016. Also, the American Cancer Society projected 26,240 new cases of stomach cancer to be diagnosed in the year 2018. The rise in the global geriatric population remains a significant growth driver. The aged populace is generally more susceptible to digestive disorders and induces high demand for diagnosis & treatment. Other factors boosting the growth of the market include the growing occurrence of diabetes and thyroid among the global population. Rigorous R&D activities to develop new drugs and therapies are also likely to augur the growth of the market over the forecast period. Unhealthy diet and a sedentary lifestyle can also be considered as a major reason for the growth of the global dyspepsia market. Due to the current busy lifestyle, consumers are more prone to consuming on-the-go food items which are generally unhealthy and cause digestive disorders. Additionally, such a situation is worsened by smoking and alcohol consumption which favors market growth. On the flipside, the growth of the market might be hindered by high costs associated with diagnostic tests and cut-throat competition among market players.
Segmentation
The global dyspepsia market has been segmented based on diagnosis, treatment, and end user.
By diagnosis, the global dyspepsia market has been segmented into blood tests, breath tests, stool tests, endoscopy, X-ray, CT scan, and others.
By treatment, the global dyspepsia market has been segmented into antacids, antibiotics, h2 blockers, proton pump inhibitors (PPIs), prokinetics, psychological therapies, and others. The antacids segment has been further segmented into calcium carbonate, loperamide, simethicone, sodium bicarbonate, and others. The antibiotic segment has been further segmented into amoxicillin, clarithromycin, metronidazole, and others.  The H2 blockers segment has been further segmented into cimetidine, famotidine, nizatidine, ranitidine, and others. The Proton pump inhibitors (PPIs) segment has been further segmented into esomeprazole, lansoprazole, and omeprazole. Prokinetics are categorized into bethanechol and metoclopramide.
By end user, the global dyspepsia market has been segmented into hospitals and clinics, ambulatory surgical centers, pharmacies, diagnostic centers, and others.
Regional Analysis
By region, the global dyspepsia market has been segmented into the Americas, Europe, Asia-Pacific (APAC), and the Middle East and Africa (MEA).
Competitive Landscape
The notable players in the global dyspepsia market are
  • Allergan Plc,
  • Takeda Pharmaceutical Company,
  • Abbott Laboratories,
  • Johnson & Johnson,
  • Eisai Co., Ltd.,
  • Sanofi,
  • Bayer AG,
  • Salix Pharmaceuticals,
  • AstraZeneca,
  • Boehringer Ingelheim GmbH,
Posted by at No comments:
Subscribe to: Posts (Atom)